Publication: The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer
Open/View Files
Date
2017
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Erstad, Derek J., Andrew M. Tager, Yujin Hoshida, and Bryan C. Fuchs. 2017. “The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer.” Molecular & Cellular Oncology 4 (3): e1311827. doi:10.1080/23723556.2017.1311827. http://dx.doi.org/10.1080/23723556.2017.1311827.
Research Data
Abstract
ABSTRACT Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.
Description
Other Available Sources
Keywords
ATX, chemoprevention, cirrhosis, fibrosis, HCC, hepatocellular carcinoma, LPA, LPAR1, NASH, non-alcoholic steatohepatitis
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service